Fusion Antibodies
Simon Douglas is an experienced leader in the biotechnology and diagnostic sectors, currently serving as Non Executive Chairman at Abselion and Fusion Antibodies plc, alongside roles as Chief Executive at C Major Medical and Non Executive Chairman at Cambridge Nutritional Sciences plc. With a background that includes pivotal positions such as Chief Executive at Biofortuna and Executive Chairman at Lab 901, Simon has a rich history in developing innovative laboratory instruments and healthcare solutions. Educational credentials include a PhD in Antibody Imaging of Tumours and a BSc in Chemistry, both from the University of Southampton.
This person is not in any teams
This person is not in any offices
Fusion Antibodies
Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry. We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages. Fifteen of our client’s projects have advanced to clinical stages, some as far as Phase II. We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of biologics. We offer this personalised service because we know that investment at the early stages saves not only millions of dollars but also months, even years of time, on projects that go awry at later stages of development. Through our vast experience we have developed a number of our own proprietary platforms for Antibody Humanization (CRX™), Affinity Maturation (RAMP™) and Developability optimisation (ADD™). Fusion Antibodies is a publicly held company, trading on the London Stock Exchange (LSE FAB.L) with headquarters in Belfast, Northern Ireland.